跳至主要内容
临床试验/NCT01255956
NCT01255956Unknown3 期

Efficacy Evaluation of In-bare Metal Stent Restenosis Treatment With Rapamycin Eluting Stent or Paclitaxel Eluting Balloon Catheter. Study With Intravascular Ultrasound and Optical Coherence Tomography

Medical University of Warsaw8 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2010年12月1日最近更新:
适应症

试验速览

阶段
3 期
发起方
入组人数
200
试验地点
8
主要终点
Incidence of repeated restenosis angiographically evidenced

研究概览

简要总结

The aim of the study is to compare rapamycin eluting stent and paclitaxel eluting balloon catheter in the treatment of restenosis in bare metal stent.

详细描述

Study aims:

  • Clinical efficacy evaluation of different treatment's strategies, including periprocedural and long-term endpoints defined as: death, myocardial infarction, brain stroke, necessity of repeated revascularization
  • Evaluation of intravascular ultrasound (IVUS) as an optimisation method for direct and long-term revascularization effects
  • Evaluation of optical coherence tomography as an optimisation method for direct and long-term revascularization effects
  • Evaluation of late lumen loss and neointimal hyperplasia in stent in long-term follow-up
  • Analysis of direct and indirect medical costs of alternative treatment strategies

Study group:

200 patients with symptomatic restenosis evidenced angiographically in bare metal stent implanted in native coronary artery. Patients will be randomised to 2 therapeutic groups:

  • Patients treated with rapamycin eluting stent (n=100)
  • Patients treated with paclitaxel eluting balloon catheter (n=100)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • at least 18 years of age
  • symptomatic restenosis in bare metal stent implanted in native coronary artery
  • angina pectoris
  • ischemia evidenced by non-invasive diagnostic tests
  • angiographically evidenced in-stent restenosis > 50% assessed by quantitative coronary angiography (QCA)
  • vessel diameter > 2,5 mm

排除标准

  • myocardial infarction within less than past 72 hours
  • heart failure with left ventricular ejection fraction (LVEF) < 30%
  • chronic renal failure with significant impairment of glomerular filtration (creatinine > 2 mg/dl)
  • hypersensitivity or contraindication to acetylsalicylic acid, clopidogrel, heparin, abciximab, rapamycin, paclitaxel
  • hypersensitivity to contrast
  • other diseases that may cause significant deterioration in long-term prognosis
  • acute or chronic inflammatory diseases
  • patients who are unwilling to consent for participation in the study
  • Angiographic exclusion criteria:
  • significant stenosis in left main coronary artery (LM)
  • multivessel disease qualifying for coronary artery bypass grafting (CABG)
  • anatomical localization and morphology that preclude optimal percutaneous intervention intervention's (PCI) result or intravascular ultrasound (IVUS) or optical coherence tomography performance
  • vessel diameter < 2,5 mm
  • restenotic lesion length > 30 mm

结局指标

主要结局

Incidence of repeated restenosis angiographically evidenced

时间窗: at 9 months

Neointimal volume assessed by intravascular ultrasound (IVUS)

时间窗: at 9 months

Late lumen loss and neointimal volume assessed by optical coherence tomography (OCT)

时间窗: at 9 months

次要结局

  • Incidence of repeated target lesion revascularization (TLR)(at 9 months)
  • Incidence of repeated target vessel revascularization (TVR)(at 9 months)
  • Incidence of death(at 9 months)
  • Incidence of myocardial infarction(at 9 months)
  • Incidence of brain stroke(at 9 months)
  • Incidence of in-stent thrombosis(at 9 months)

研究者

发起方
Medical University of Warsaw
申办方类型
Other

研究点 (8)

Loading locations...

相似试验